ADH1C and colorectal carcinoma: ADH1C has been shown to inhibit the progression of CRC through the ADH1C/PHGDH/PSAT1/serine metabolic pathway (38), and downregulation of ADH1C has been associated with poor prognosis in patients with CRC (39).